WHO ICTRP trial
PHASE II OPen Label, MULTICENTER, PROSPECTIVE, RANDOMIZED, AGE RELATED MACULAR…
CTRI/2009/091/000385 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2009/091/000385 |
|---|---|
| Public title | PHASE II OPen Label, MULTICENTER, PROSPECTIVE, RANDOMIZED, AGE RELATED MACULAR DEGENERATION, COMPARATOR controlled, STUDY evaluating PF 04523655 VERSUS RANIBIZUMAB IN the treatment of SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONet study) |
| Scientific title | Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study). - Not applicable |
| Primary sponsor | Pfizer Limited |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: null- Age Related Macular Degeneration |
| Interventions | Intervention1: Arm 2: Experimental Intervention: Drug: PF-04523655: Drug: PF-04523655 0.5 mg of Lucentis given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given every 2 weeks from Week 4 to Week 12 Intervention2… |
| Registration date | Jun 24, 2009 |
| Target size | 150 |
| Secondary IDs | B0451001;NCT00713518 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: